Esperion Therapeutics, Inc. financial statements, including revenue, expenses, profit, and loss

The total revenue of ESPR for the last quarter is 73.83 M USD, and it's 46.39% lower compared to the previous quarter. The net income of Q2 24 is -61.92 M USD.